Dashboard
1
Negative results in Sep 25
- INTEREST(9M) At CNY 16.99 MM has Grown at 13.49%
- ROCE(HY) Lowest at 14.04%
- INTEREST COVERAGE RATIO(Q) Lowest at 1,571.7
2
With ROE of 14.14%, it has a expensive valuation with a 4.99 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,266 Million (Mid Cap)
35.00
NA
0.22%
-0.05
12.86%
4.01
Revenue and Profits:
Net Sales:
398 Million
(Quarterly Results - Mar 2026)
Net Profit:
86 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.68%
0%
-15.68%
6 Months
-19.98%
0%
-19.98%
1 Year
-36.73%
0%
-36.73%
2 Years
-65.73%
0%
-65.73%
3 Years
-76.85%
0%
-76.85%
4 Years
-71.36%
0%
-71.36%
5 Years
-74.47%
0%
-74.47%
Eyebright Medical Technology (Beijing) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
44.26%
EBIT Growth (5y)
36.90%
EBIT to Interest (avg)
83.12
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.42
Tax Ratio
9.26%
Dividend Payout Ratio
17.06%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.21%
ROE (avg)
12.24%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
4.99
EV to EBIT
32.13
EV to EBITDA
23.33
EV to Capital Employed
5.36
EV to Sales
9.16
PEG Ratio
1.75
Dividend Yield
0.18%
ROCE (Latest)
16.68%
ROE (Latest)
14.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
398.20
338.30
17.71%
Operating Profit (PBDIT) excl Other Income
101.20
15.70
544.59%
Interest
5.80
6.00
-3.33%
Exceptional Items
-0.30
0.10
-400.00%
Consolidate Net Profit
85.80
-38.00
325.79%
Operating Profit Margin (Excl OI)
254.00%
-96.40%
35.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 17.71% vs -5.42% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 325.79% vs -153.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,473.60
1,403.30
5.01%
Operating Profit (PBDIT) excl Other Income
533.30
573.60
-7.03%
Interest
23.20
21.00
10.48%
Exceptional Items
-72.00
-4.20
-1,614.29%
Consolidate Net Profit
240.60
387.10
-37.85%
Operating Profit Margin (Excl OI)
239.90%
305.00%
-6.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.01% vs 48.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -37.85% vs 35.30% in Dec 2024
About Eyebright Medical Technology (Beijing) Co., Ltd. 
Eyebright Medical Technology (Beijing) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






